Recorded fact · drug.label_indication
drug.label_indication for romosozumab-aqqg|osteoporosis
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 8592c260 resolves to.
The record
| Fact id | 8592c260104d7055c4f39d29 |
|---|---|
| Entity | drug: romosozumab-aqqg|osteoporosis |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260716 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
EVENITY is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture;
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 1ad479de415875050c16f9db447a9c9095fc954beafba79227459f7d8e277ecf.
The value
{
"ingredient": "Romosozumab-Aqqg",
"conditionId": "osteoporosis",
"conditionName": "Osteoporosis",
"matchedAlias": "osteoporosis",
"context": "indication",
"brand": "Evenity",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "471baba2-7154-4488-9891-0db2f46791e7",
"labelEffectiveTime": "20260716",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 06f7888c3dd5b27092b349df1400d433991911b68a03399261335183f7a74ebb.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.